Methylene blue adjuvant therapy of schizophrenia

Clinical Neuropharmacology

Volumn 20, Issue 4, 1997, Pages 357-363

  Deutsch, Stephen I ^a,b   Rosse, Richard B ^a   Schwartz, Barbara L ^a   Fay McCarthy, Maureen ^a   Rosenberg, Paul B ^a   Fearing, Kim ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medical Center   (United States)

Author keywords

Adjuvant therapy; Antipsychotic; Nitric oxide stimulated guanylyl cyclase; NMDA receptor complex; Shizophrenia

Indexed keywords

6 ANILINO 5,8 QUINOLINEQUINONE; FLUPHENAZINE; GUANYLATE CYCLASE; HALOPERIDOL; LUBELUZOLE; METHYLENE BLUE; MOLINDONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RISPERIDONE; RO 87926; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030855293     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199708000-00008     Document Type: Article

References (28)

1. Karatinos J. Rosse RB, Deutsch SI. The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol 1995;18:482-99.
2. Deutsch SI, Rosse RB, Paul SM, et al. 7-nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice. Neuropsychopharmacology 1996;15:37-43.
3. Akbarian S, Bunney WE, Potkin SG, et al. Altered distribution of nicotinamide-adeninc dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993;50:169-77.
4. Akbarian S, Vinuela A, Kim JJ. Potkin SG, Bunney WE, Jones EG. Distorted distribution of nicotinamideadenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-86.
5. Karson CN, Garcia-Rill E, Biederman J, Mrak RE. Husain MM. Skinner RD. The brainstem reticular formation in schizophrenia. Psychiatry Res 1991;40:31-48.
6. Dawson TM, Dawson VL, Synder SH. A novel neuronal messenger molecule in brain. The free radical, nitric oxide. Ann Neurol 1992;32:297-311.
7. Moncada S, Higgs A. The L-arginine-nitnc oxide pathway. N Engl J Med 1993;329:2002-12.
8. Murad F. The role of nitric oxide in modulating guanylyl cyclase. Neurotransmission 1994;10:1-4.
9. Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur Heart J 1993;14(suppl):22-6.
10. Martin W, Villani GM, Jothianandan D. Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985;232:708-16.
11. Kawada T, Ishibashi T, Sasage H, Kato K, Imai S. Modification by LY 83583 and methylene blue of relaxation induced by nitric oxide, glyceryl trinitrate, sodium nitroprusside and atriopeptin in aortae of the rat, guinea-pig and rabbit. Gen Pharmacol 1994;25:1361-71.
12. Moncada S, Palmer RM, Gryglewski RJ. Mechanism of action of some inhibitors of endothelium-derived relaxing factor. Proc Natl Acad Sci U. S. A. 1986;83:9164-8.
13. Narsapur S, Naylor G. Methylene blue: a possible treatment for manic depressive psychosis. J Affect Disord 1983;5:155-61.
14. Naylor G, Dick D, Johnston B, Hopwood S, Dick E, Smith A, Kay D. Possible explanation for therapeutic action of lithium and a possible substitute (methylene blue). Lancet 1981;2:1175-6.
15. Bodoni, P. Le bleu de methylene comme calmant chez les alienes. Semaine Med 1899;7:56.
16. Deutsch SI, Hitri A. Measurement of an explosive behavior in the mouse induced by MK-801, a PCP analogue. Clin Neuropharmacol 1993;16:251-7.
17. Rosse RB, Mastropaolo J, Koetzner L, Morn CB, Sussman DM, Deutsch SI. Computerized measurement of MK-801 elicited hyperactivity and popping in mice. Clin NeuroPharmacol 1995;18:448-57.
18. Overall JE, Gorham DE. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
19. Andreasen NC. Negative symptoms in schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39:784-8.
20. Bonato GW. Manual for the ECDU Assessment Battery. 2nd revision. Washington, DC; U. S. Department of Health and Human Services, 1970.
21. Diener HC, Hacke W, Hennerichi M, Radberg J, Hanston L., DeKeyser J. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke 1996;27:76-81.
22. Lesage AS, De Loore KL. Osikowska-Evers B, Peters L, Leysen JF. Lubeluzole, a novel neuroprotectant, inhibits the glutamate activated NOS pathway. Soc Neurosci Abstr 1994;20:185
23. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide sensitive guanylyl cyclase by 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one. Mol Pharmacol 1995;48:184-8.
24. Luo D, Das S, Vincent SR. Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase. Eur J Pharmacol 1995;290:247-51.
25. Mayer B, Brunner F. Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993:45:367-74.
26. Dawson TM, Hung K, Dawson VL, Steiner JP. Snyder SH. Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Ann Neurol 1995;37:115-8.
27. Marshall JJ. Wei EP, Kontos HA. Independent blockade of cerebral vasodilation from acetylholine and nitric oxide. Am J Physiol 1988;255:51-6.
28. Wolin MS, Chery PD, Rodenberg JM, Messina EJ, Kaley G. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Ther 1990;254:872-6.